A new nature medicine review has listed clinical trials targeting toll-like receptors. These including 3 preclinical studies using cpG-ODNs against TLR9 by Dynavax Astra-Zeneca, Coley / Sanofi-Aventis and Idera / Novartis. Lets wait and see…